PMC:7799377 / 39452-39618
Annnotations
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T264 | 0-166 | Sentence | denotes | Third-line strategies for neuroinflammation in COVID patients may carry higher risks, and include such pharmacological agents as cyclophosphamide and rituximab [121]. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1372 | 53-61 | Species | denotes | patients | Tax:9606 |
| 1373 | 129-145 | Chemical | denotes | cyclophosphamide | MESH:D003520 |
| 1374 | 150-159 | Chemical | denotes | rituximab | MESH:D000069283 |
| 1382 | 26-43 | Disease | denotes | neuroinflammation | MESH:D020078 |
| 1383 | 47-52 | Disease | denotes | COVID | MESH:C000657245 |